Table 2.
Antibody titers of IVIG products
| Seasons | Virus strain | HI titers
|
VN titers
|
||||
|---|---|---|---|---|---|---|---|
| V-IH (IgG: 5%) |
Poly-N (IgG: 5%) |
Poly-N (IgG: 10%) |
V-IH (IgG: 5%) |
Poly-N (IgG: 5%) |
Poly-N (IgG: 10%) |
||
| A H1N1 | |||||||
| 2012/13 | A/California/7/2009 | 147 ± 100 (n = 27) |
NE | NE | 450 ± 402 (n = 27) |
NE | NE |
| 2013/14 | A/California/7/2009 | 255 ± 81 (n = 22) |
224 ± 105 (n = 10) |
432 ± 227 (n = 10) |
1135 ± 275 (n = 22) |
864 ± 454 (n = 10) |
3136 ± 2100 (n = 10) |
| 2014/15 | A/California/7/2009 | 320 ± 0 (n = 19) |
267 ± 80 (n = 9) |
512 ± 175 (n = 5) |
1482 ± 480 (n = 19) |
1138 ± 282 (n = 9) |
2048 ± 701 (n = 5) |
| A H3N2 | |||||||
| 2012/13 | A/Victoria/361/2011 | 178 ± 51 (n = 27) |
NE | NE | 1256 ± 123 (n = 27) |
NE | NE |
| 2013/14 | A/Texas/50/2012 | 178 ± 60 (n = 22) |
144 ± 34 (n = 10) |
240 ± 84 (n = 10) |
1571 ± 549 (n = 22) |
1664 ± 810 (n = 10) |
3456 ± 1484 (n = 10) |
| 2014/15 | A/New York/39/2012 | 152 ± 25 (n = 19) |
116 ± 42 (n = 9) |
224 ± 88 (n = 5) |
2425 ± 842 (n = 19) |
1489 ± 675 (n = 9) |
3584 ± 1402 (n = 5) |
| B | |||||||
| 2012/13 | B/Wisconsin/01/2010 | 314 ± 175 (n = 27) |
NE | NE | 1280 ± 0 (n = 27) |
NE | NE |
| 2013/14 | B/Massachusetts/02/2012 | 465 ± 163 (n = 22) |
480 ± 169 (n = 10) |
640 ± 0 (n = 10) |
2095 ± 630 (n = 22) |
2048 ± 661 (n = 10) |
4352 ± 1237 (n = 10) |
| 2014/15 | B/Massachusetts/02/2012 | 589 ± 120 (n = 19) |
640 ± 0 (n = 9) |
896 ± 351 (n = 5) |
2088 ± 634 (n = 19) |
1422 ± 427 (n = 9) |
4608 ± 1145 (n = 5) |
Notes: Data are expressed as mean ± SD. V-IH and Poly-N are manufactured by different processes. Also, Poly-N comes in two different IgG concentrations: 5% (50 mg/mL) and 10% (100 mg/mL).
Abbreviations: IVIG, intravenous immunoglobulin; HI, hemagglutination inhibition; VN, virus neutralizing; V-IH, Venoglobulin IH; IgG, immunoglobulin G; Poly-N, Nisseki Polyglobin-N; NE, not examined; SD, standard deviation.